SPIN 2022

IMIDs in Adults and Children: New Developments

Therapies for atopic dermatitis: still moving forward

Presented By

Prof. Christian Vestergaard, Aarhus University Hospital, Denmark

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:58

Children with AD: high risk of bacterial infections in carriers of a filaggrin gene variant

Presented By

Prof. Alina Suru , Carol Davila University of Medicine and Pharmacy, Romania

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:53

Men on biologics report fewer adverse events than women

Presented By

Ms Jette van Lint , Pharmacovigilance Centre Lareb, the Netherlands

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:51

Conceptual framework of adverse drug reactions may improve treatment of patients with IMIDs

Presented By

Ms Jette van Lint , Pharmacovigilance Centre Lareb, the Netherlands

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:49

No adverse pregnancy outcomes in patients exposed to baricitinib

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:47

Psoriasis: The Beat Goes On

Systemic treatment for psoriasis: what is on the horizon?

Presented By

Prof. Diamant Thaci , University of Lübeck, Germany

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:45

Topical therapy in psoriasis: an important partner in combination therapy

Presented By

Prof. Peter van de Kerkhof, Radboud University Medical Centre, the Netherlands

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:40

GPP flares: pronounced undertreatment is common

Presented By

Dr Wendell Valdecantos , Boehringer Ingelheim Pharmaceuticals, CT, USA

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:38

All patients with GPP benefit from IL-36 inhibitor therapy

Trial

Phase 2, Effisayil 1

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:37

IL-17A/F inhibitor bimekizumab shows higher response and maintenance rates compared with secukinumab

Trial

Phase 3, BE RADIANT

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:35

Greater PASI reductions lead to less impairment in social and sexual life

Trial

Phase 3, VOYAGE 1, VOYAGE 2

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:32

Paediatric psoriasis: ixekizumab beneficial in difficult-to-treat areas

Presented By

Dr Marieke Seyger , Radboud University Medical Centre, the Netherlands

Trial

Phase 3, IXORA-PEDS

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:30

Psoriasis patients see great benefit in achieving complete skin clearance

Presented By

Prof. Matthias Augustin , University Medical Centre Hamburg, Germany

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:25

The Future Is Bright for Vitiligo

Where Are We Now in Hidradenitis Suppurativa

IHS4 better suited as an outcome measure in HS trials?

Presented By

Prof. Thrasyvoulos Tzellos, Nordland Hospital Trust, Norway

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:18

New treatments for HS: IL-17 inhibitors next in practice?

Presented By

Dr Axel Villani, University of Lyon, France & Prof. Thrasyvoulos Tzellos, Nordland Hospital Trust, Norway

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:05

New Treatment Options in Alopecia Areata

Alopecia areata: light at the end of the tunnel

Presented By

Prof. Maryanne Senna , Harvard Medical School, MA, USA

Trial

Phase 3, BRAVE-AA1, BRAVE-AA2

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:01

Alopecia areata pathogenesis: known genetic background, unknown environmental triggers

Presented By

Prof. Rodney Sinclair , University of Melbourne, Australia

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 09:56

Best of the Posters